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Abstract 
Background 
In colorectal carcinoma (CRC), activation of the Raf/MEK/ERK signaling pathway is 
commonly observed. In addition, the commonly used 5FU-based chemotherapy in patients 
with metastatic CRC was found to enrich a subpopulation of CD26+ cancer stem cells 
(CSCs). As activation of the Raf/MEK/ERK signaling pathway was also found in the CD26+ 
CSCs and therefore, we hypothesized that an ATP-competitive pan-Raf inhibitor, Raf265, is 
effective in eliminating the cancer cells and the CD26+ CSCs in CRC patients. 
Methods 
HT29 and HCT116 cells were treated with various concentrations of Raf265 to study the anti-
proliferative and apoptotic effects of Raf265. Anti-tumor effect was also demonstrated using 
a xenograft model. Cells were also treated with Raf265 in combination with 5FU to 
demonstrate the anti-migratory and invasive effects by targeting on the CD26+ CSCs and the 
anti-metastatic effect of the combined treatment was shown in an orthotopic CRC model. 
Results 
Raf265 was found to be highly effective in inhibiting cell proliferation and tumor growth 
through the inhibition of the RAF/MEK/ERK signaling pathway. In addition, anti-migratory 
and invasive effect was found with Raf265 treatment in combination with 5FU by targeting 
on the CD26+ cells. Finally, the anti-tumor and anti-metastatic effect of Raf265 in 
combination with 5FU was also demonstrated. 
Conclusions 
This preclinical study demonstrates the anti-tumor and anti-metastatic activity of Raf265 in 
CRC, providing the basis for exploiting its potential use and combination therapy with 5FU 
in the clinical treatment of CRC. 
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Background 
Colorectal carcinoma (CRC) is a common cancer worldwide [1]. Currently, surgery remains 
the first-line treatment in localized CRC. Among patients with metastatic CRC (mCRC), only 
10-25% are suitable for surgical resection and the five-year survival rate is around 30-40% 
[2-4]. However, the prognosis remains poor for unresectable mCRC patients and a median 
survival of up to 24 months was reported despite advances in chemotherapy and molecular 
targeting drugs [5]. Intrinsic and acquired chemoresistance remains the major reason for the 
failure of chemotherapy. A recent study from our team suggests that chemotherapy with 
fluorouracil (5FU) enriches a subpopulation of CD26+ cells and CD26+ cells are the cancer 
stem cells (CSCs) responsible for metastasis, enhanced invasiveness and chemoresistance in 
CRC [6]. This suggested that conventional chemotherapy treatment is not effective enough to 
completely eradicate the tumor with metastatic stem cells. 
Constitutive activation of the Raf/MEK/ERK pathway is commonly observed in CRC due to 
overexpression or mutations of the upstream receptor tyrosine kinases (EGFR, PDGFR or 
VEGFR) or the downstream effectors (Ras, Raf, MEK or ERK). Since this signaling pathway 
plays a central role in controlling cell proliferation, survival, differentiation and metastasis 
[7], a number of therapeutics targeting on the Raf/MEK/ERK pathway has been established 
[8]. Raf265, a highly selective inhibitor of Raf (Braf, Craf and mutant Braf) and VEGFR 
kinase, is an orally bioavailable small molecule [9]. The anti-proliferative effect of Raf265 
has been published in melanoma [10] and neuroendocrine tumor cells [11]. The study of the 
pharmacokinetics and pharmacodynamics of Raf265 has also entered the Phase I/II study in 
patients with locally advanced or metastatic melanoma. 
In this study, our aim is to validate the efficacy of Raf265 on inhibiting tumor growth and 
preventing metastasis in CRC. A further investigation of the effect of Raf265 on CD26+ cells 
treated with 5FU was carried out. By using an in vivo study, we further provide evidence of 
reduced liver and lung metastasis by Raf265 treatment in combination with 5FU. Therefore, 
with this study, the pre-clinical anti-tumor and anti-metastatic effects of Raf265 can be 
demonstrated, which provides the basis for exploiting the use of Raf265 as a potential 
treatment against mCRC. 
Results 
Anti-proliferative and apoptotic effects of Raf265 on HT29 and HCT116 cells 
with the inhibition of Raf/MEK/ERK signaling pathway 
The effect of Raf265 on cell proliferation was measured by the MTT cell proliferation assay 
and the soft agar colony formation assay. Treatment of Raf265 for 72 hours inhibited cell 
proliferation in a dose dependent manner with an IC50 of 2.08 µM and 1.83 µM in HT29 and 
HCT116 cells, respectively (Figure 1A). Dose-dependent reduction in the number and size of 
colony formed in soft agar was also observed (Figure 1B). When treated with 1 µM Raf265 
for 3 weeks, the number of colony formed reduced from 38.6 ± 6.5 and 28.3 ± 3.5 to 1.67 ± 
1.15 and 0.67 ± 0.58 colonies for HT29 and HCT116 cells, respectively. 
Figure 1 The anti-proliferative effect of Raf265 on HT29 and HCT116 cells. A. Cells 
were treated with Raf265 at 0–50 µM and MTT assay was performed. B. Cells were 
suspended in the solidified agarose at the indicated concentrations of Raf265. Representing 
images under a phase-contrast microscopy at 40x magnification and an amplified view at 
400x magnification were shown at the upper panel. The number of colony formed was then 
counted and the bar chart presenting the average number of colony formed was shown at the 
lower panel. 
We then determined the apoptotic effect of Raf265 on HT29 (Figure 2A) and HCT116 
(Figure 2B) cells with the annexin V/PI assay. After exposing the cells to the indicated 
concentrations of Raf265 for 48 h, the numbers of apoptotic cells increase with increasing 
concentrations of Raf265. The percentages of annexin V positive cells increase from 10.5% ± 
2.41% at 0 µM Raf265 to 35.1% ± 6.77% at 15 µM Raf265 in HT29 cells and from 20.1% ± 
2.99% at 0 µM Raf265 to 42.2% ± 3.58% 15 µM Raf265 in HCT116 cells. To study if the 
apoptotic effect of Raf265 is a caspase-dependent process, flow cytometry was used to study 
the activities of caspase 9, caspase 8 and caspase 3 in HT29 (Figure 2C) and HCT116 (Figure 
2D) cells. After treatment with 10 µM of Raf265 for 2 days, we found the increases of 
activities of caspase 9 (HT29: from 2.11% ± 0.33% to 4.52% ± 0.56%; HCT116: 3.25% ± 
0.25% to 5.13% ± 0.34%), caspase 8 (HT29: from 2.45% ± 0.40% to 5.07% ± 0.42%; 
HCT116: 1.34% ± 0.23% to 3.98% ± 0.29%) and caspase 3 (HT29: from 1.11% ± 0.17% to 
2.4% ± 0.20%; HCT116: 2.84% ± 0.35% to 5.98% ± 0.74%). 
Figure 2 The apoptotic effect of Raf265 on HT29 and HCT116 cells. A. HT29 cells and B. 
HCT116 cells were treated with 0–15 µM Raf265 and Annexin V assay was performed. 
Representing flow diagrams at 0 and 15 µM were shown at the upper panel and bar charts 
presenting the average percentage of annexin V positive cells after treatment were shown at 
the lower panel. C. HT29 cells and D. HCT116 cells were treated with 0–10 µM Raf265. 
Caspase 3, caspase 8 and caspase 9 activities were analyzed by flow cytometry. Data are 
presented as means ± SD from three independent experiments and statistical analysis was 
performed by one-way ANOVA. * p < 0.05 versus untreated control. 
In order to validate the inhibitory effect of Raf265 on the Raf/MEK/ERK signaling pathway, 
we further performed the western blot analysis on the total expression and phosphorylation of 
MEK and ERK after 2 hours treatment with the indicated concentrations of Raf265 in serum 
free medium. Treatment with increasing concentration of Raf265 inhibited MEK and ERK 
phosphorylation significantly in both HT29 (Figure 3A) and HCT116 (Figure 3B) cells. With 
the addition of EGF, which binds EGFR and activates the Raf/MEK/ERK signaling pathway, 
the inhibition of phosphorylation by Raf265 was still significant. 1 µM U0126, an MEK 
inhibitor, was added as a control to demonstrate the inhibition of ERK phosphorylation. The 
total protein expressions of MEK and ERK were not change with the Raf265 treatment. 
Figure 3 Inactivation of the Raf/MEK/ERK signaling pathway by Raf265 on HT29 and 
HCT116 cells. A. HT29 cells and B. HCT116 cells were treated with 0–10 µM Raf265 with 
or without the addition of EGF, or 10 µM U0126. Representing blots of the western blot 
analysis of the total expression and phosphorylation of MEK and ERK were shown. The 
expression level of β-actin was used as the loading control. At the lower panels, bar charts 
presenting the ratio of p.MEK vs. TL. MEK and p.ERK vs TL. ERK were shown. Data are 
presented as means ± SD from three independent experiments and statistical analysis was 
performed by one-way ANOVA. * p < 0.05 versus untreated control of the corresponding cell 
lines. 
Anti-tumor and effect of Raf265 on HT29 and HCT116 cells 
An in vivo study was used to demonstrate the anti-tumor effect of Raf265. Intraperitoneal 
injection of Raf265 at 0.2 mg/kg twice a week for 16 weeks significantly reduced the 
subcutaneous tumor weight starting from week 12 after injection (Figure 4A). The anti-tumor 
effect was similar between tumors derived from HT29 and HCT116 with a reduction of 
tumor weight by 53.8% and 50.4% respectively. The anti-angiogenic effect was also 
demonstrated by the reduction of CD31 expression expressed by the tumors raised from 
HT29 and HCT116 cells (Figure 4B). 
Figure 4 The anti-tumor effect of Raf265 on HT29 and HCT116 cells. A. The average 
tumor weight of mice treated with Raf265 were shown. Data are presented as means ± SD 
from 6 nude mice and statistical analysis was performed by one-way ANOVA. * p < 0.05 
versus the vehicle control group with the xenograft tumors from the corresponding cell lines. 
B. Representing diagrams of the IHC staining of CD31 (magnification: 400x) of the primary 
tumor from HT29 and HCT116 cells of the vehicle control group and treatment group were 
shown. At the lower panel, a bar chart presenting the scoring of IHC staining of CD31 based 
on the percentage and intensity of the positively stained cells under high power (400x) 
microscopy was shown. Data are presented as means ± SD from 6 mice in each group. * p < 
0.05 vs saline group by one-way ANOVA. 
Activated Raf/MEK/ERK signaling pathway in CD26+ cells 
As Raf265 targets on the Raf/MEK/ERK signaling pathway, western blotting analysis was 
performed to compare the Braf expression of CD26+ and CD26− cells, in order to predict the 
efficacy of Raf265 on CD26+ CSCs. Five tumor specimens were dissected and sorted for 
CD26+ and CD26− cells. CD26+ cells demonstrated a higher expression of Braf than that of 
the CD26− cells (Figure 5). CD26+ cells also demonstrated higher phosphorylation levels of 
MEK and ERK. The higher Braf expression with enhanced phosphorylation of MEK and 
ERK in CD26+ cells suggested a possible therapeutic effect of Raf265 on CD26+ CSCs. 
Figure 5 Activated Raf/MEK/ERK signaling pathway of CD26+ cells. CD26+ and CD26− 
cells sorted from tumor samples, HT29 and HCT116 cells were lysed and subjected to 
western blot analysis. Representing blots of the expression of total Braf, MEK and ERK, and 
the phosphorylation of MEK and ERK were shown. The expression level of β-actin was used 
as the loading control. At the lower panel, a bar chart presenting the ratio of Braf vs. β-actin, 
p.MEK vs. TL. MEK and p.ERK vs TL. ERK was shown. Data are presented as means ± SD 
from three independent experiments and statistical analysis was performed by one-way 
ANOVA. * p < 0.05 versus CD26− cells of the corresponding samples. 
Reduced proliferation and self-renewal ability of CD26+ cells by Raf265 
As mentioned, treatment with chemotherapy can easily develop multi-drug resistance and 
enrichment of CD26+ subpopulation can also result in chemoresistance and enhanced 
metastasis. In this study, treatment of HT29 cells with 5FU was found to increase the 
percentage of CD26+ cells by 2 folds whereas treatment with Raf265 did not change the 
percentage of CD26+ cells (Figure 6A). In addition, combined treatment of Raf265 and 5FU 
significantly restored the percentage of CD26+ cells to the baseline level. 
Figure 6 Anti-proliferative effect of Raf265 on CD26+ cells. A. Cells were treated with 
different combinations of Raf265 and 5FU. The percentage of CD26+ cells was determined. 
B. CD26+ cells with single cell suspensions were treated with different concentrations of 
Raf265 for the sphere formation assay. After 14 days, spheres were disaggregated and 
reseeded for the second passage of sphere formation. Representing images under a phase-
contrast microscopy at 40x magnification were shown at the upper panel. The numbers of 
spheres formed were then quantified after 14 days of incubation and the bar chart presenting 
the numbers of spheres formed was shown at the lower panel. HT29 cells with 5FU resistance 
were treated with C. 5FU at 0–50 µM and D. Raf265 at 0–10 µM and MTT assay was 
performed. Data are presented as means ± SD from three independent experiments and 
statistical analysis was performed by one-way ANOVA. * p < 0.05 versus untreated control. 
Serial passage of CD26+ cells treated with Raf265 was done to study the effect of Raf265 on 
the ability of self-renewal of CD26+ cells (Figure 6B). For the first passage, the number of 
sphere formed reduced from 25.0 ± 5.0 to 4.0 ± 3.6 when treated with 0.1 µM Raf265. For 
the second passage, the number of sphere formed reduced from 17.7 ± 2.5 to 1.3 ± 0.6 when 
treated with 0.1 µM Raf265. No sphere can be found when treated with 1 µM Raf265. 
We then developed the 5FU-R cells with an IC50 to 5FU treatment increased from 14.2 µM 
for the CTL cells to 85.7 µM for the 5FU-R cells (Figure 6C). Both 5FU-R and CTL cells are 
sensitive towards Raf265 treatment with an IC50 of 2.43 µM and 1.06 µM, respectively 
(Figure 6D) and flow analysis of the resistant cells demonstrated an enrichment of the CD26+ 
CSCs when compared with the CTL cells (12.9% ± 0.7% in 5FU-R cells vs 5.8% ± 0.4% in 
CTL cells). 
Enhanced apoptotic effect and reduced migratory and invasive ability of 
CD26+ cells by Raf265 
We then further investigate if Raf265 is able to induce apoptosis of CD26+ cells by blocking 
the Raf/MEK/ERK signaling pathway. Cells were first sorted for CD26− and CD26+ cells and 
subjected to different treatments. Cellular apoptosis was determined by annexin V assay 
(Figure 7A). Treatment with 5FU significantly increased the percentage of annexin V 
positive cells of CD26− cells to a greater extent than the CD26+ cells (2.5 folds in CD26− cells 
vs 1.4 folds in CD26+ cells). On the other hand, treatment of Raf265 significantly increased 
the percentage of annexin V positive cells in both CD26− (by 1.4 folds) and Cd26+ (by 1.8 
folds) cells. As for the combined treatment of Raf265 and 5FU, the percentage of annexin V 
positive cells of the CD26− cells was similar to the percentage of annexin V positive cells 
when treated with 5FU alone (increased by 2.5 folds). On the other hand, the percentage of 
annexin V positive cells of CD26+ cells (increased by 2.7 folds) was higher than the 
percentage of annexin V positive cells with any of the single drug treatment. Therefore, 
treatment with Raf265 or combined treatment of Raf265 and 5FU are more effective in 
enhancing cellular apoptosis of CD26+ cells than that of the CD26− cells. 
Figure 7 Enhanced apoptotic and reduced migratory and invasive ability of Raf265 by 
targeting on CD26+ CSCs. A. CD26+ and CD26− cells were treated with different 
combinations of Raf265 and 5FU and the percentage of annexin V positive cells were 
analyzed. After treatment, representing view under 100x magnification of the B. migrated 
and C. invaded cells were shown at the upper panel and the average numbers of the B. 
migrated and C. invaded cells were plotted and shown at the lower panel. Data are presented 
as means ± SD from three independent experiments and statistical analysis was performed by 
one-way ANOVA. * p < 0.05 versus untreated control, ** p < 0.05 versus 0 µM Raf265 and 
10 µM or 5 µM 5FU as indicated and # p < 0.05 versus CTL cells. *** p < 0.05 versus 1 µM 
Raf265 and 0 µM 5FU. 
The migratory (Figure 7B) and invasive (Figure 7C) ability of the CD26+ cells were also 
studied after single and combined treatment of Raf265 and 5FU. No significant change in 
number of migrated and invaded cells when treatment with 5FU alone. A significant decrease 
in number of migrated cells (by 1.5 folds) and invaded cells (by 2.2 folds) were found when 
treated with Raf265 and combined treatment of Raf265 and 5FU further reduced the number 
of migrated cells (by 2.3 folds) and invaded cells (by 5 folds) of the CD26+ cells. Therefore, 
treatment with Raf265 or combined treatment of Raf265 and 5FU reduced the migratory and 
invasive ability of the CD26+ cells. 
Anti-tumor effect of Raf265 in combination with 5FU 
We further study the effect of combined treatment of Raf265 and 5FU using an animal model 
(Figure 8). Drugs were administrated 2 weeks after tumor inoculation in the cacal wall. 
Single or combined treatment was tolerated with no lethality and no significant weight loss 
was observed in both tumors derived from HT29 cells (Figure 8A) and HCT116 cells (Figure 
8B). For the HT29 cells derived tumor, single treatment with Raf265 at 10 and 20 mg/kg 
body weight, and 5FU at 20 mg/kg body weight significantly reduced the bioluminescence 
signals produced from tumor cells by 56.6%, 82.2% and 35.0%, respectively when compared 
with the control group whereas combined treatment of 5FU with Raf265 at 10 and 20 mg/kg 
body weight significantly reduced the bioluminescence signals by 76.7% and 92.0%, 
respectively when compared with the control group (Figure 8C). As for the HCT116 cells 
derived tumor, single treatment with Raf265 at 10 and 20 mg/kg body weight and 5FU at 20 
mg/kg body weight significantly reduced the bioluminescence signals produced from tumor 
cells by 66.1%, 88.6% and 72.7%, respectively when compared with the control group 
whereas combined treatment of 5FU with Raf265 at 10 and 20 mg/kg body weight 
significantly reduced the bioluminescence signals by 89.5% and 96.6%, respectively when 
compared with the control group (Figure 8D). Therefore as expected, single and combined 
drug treatment significantly reduced the primary tumor size in this mouse orthotopic model. 
Figure 8 Anti-tumor effect of Raf265 in combination with 5FU. 3 weeks after inoculation 
of a xenograft tumor to the cecal wall of NOD/SCID mice, Raf265 was administered p.o. 
twice a week whereas 5FU was administered i.p. once a week for 4 weeks. Mice were 
sacrificed at week 4 and body weights of mice with tumors from A. HT29 and B. HCT116 
cells were monitored. Representing mice with tumors from C. HT29 and D. HCT116 cells 
were shown in the upper panel. The average bioluminescence signals detected were also 
plotted and shown in the lower panel. Data are presented as means ± SD from 6 mice and 
statistical analysis was performed by one-way ANOVA. * p < 0.05 versus the vehicle control 
group with tumors from the corresponding cell lines. 
Anti-metastatic effect of Raf265 in combination with 5FU 
Besides reducing the primary tumor size, we also study if the treatment can reduce the chance 
of developing metastasis towards liver and lung, which are the common distant metastatic 
sites for CRC. The presence of liver and lung metastasis after single and combined treatment 
of Raf265 and 5FU was studied by tracking the bioluminescence signal detected from the 
specific organ (Figure 9A-D). All mice in the control group developed liver and lung 
metastasis. In general, single treatment reduced the number of cases and/or the liver and lung 
metastatic tumor size indicated by the reduction in the bioluminescence signal detected. 
Combined treatment with different concentrations of Raf265 and 5FU significantly reduced 
liver and lung metastasis. Treatment with Raf265 at 20 mg/kg body weight and 5FU at 20 
mg/kg body weight prevent both the liver and lung metastasis except one case demonstrated a 
small lung metastasis with HT29 cells derived tumor. Therefore, combined treatment with 
Raf265 and 5FU is effective in preventing lung and liver metastasis in this mouse orthotopic 
model. 
Figure 9 Anti-metastatic effect of Raf265 in combination with 5FU. Bioluminescence 
signals that were detected from the livers of mice with tumors from A. HT29 cells and B. 
HCT116 cells, and from the lungs of mice with tumors from C. HT29 cells and D. HCT116 
cells were shown at the upper panel of each graph and the average bioluminescence signals 
from the corresponding organs with positive signals were plotted and shown at the lower 
panel of each graph. Data are presented as means ± SD from 6 mice and statistical analysis 
was performed by one-way ANOVA. * p < 0.05 versus the vehicle group with tumors from 
the corresponding cell lines. 
Discussion 
Recent advances in the study of molecular targeted therapy in cancers lead to the 
development of certain inhibitors or antibodies against specific components in a signaling 
pathway, which controls cell proliferation and apoptosis. Activation of the Raf/MEK/ERK 
signaling pathway is commonly found in CRC due to the overexpression or presence of 
activating mutations of EGFR, Braf and/or Kras [12-15]. A point mutation at V600E position 
of Braf occurs in about 10% CRC patients [16]. The presence of BrafV600E mutation leads 
to a constitutively active protein, which activates the Raf/MEK/ERK signaling pathway [17] 
and BrafV600E mutation is correlated with poorer overall survival and disease-free survival 
than tumors with wild type Braf [18-21]. Therefore, in this study, the targeting effect of 
Raf265 on HT29 cells with mutant Braf and wild type Kras, and on HCT116 cells with wild 
type Braf and mutant Kras was demonstrated. RAF265 was found to be highly effective in 
inhibiting cell proliferation and tumor growth through the inhibition of the RAF/MEK/ERK 
signaling pathway. 
In this study, the anti-proliferative and anti-apoptotic effect of Raf265 was found to be 
effective in both HT29 and HCT116 cells with different Braf and Kras genetic status. 
However, several studies have demonstrated that Raf inhibitors were only effective in cancers 
with wild type Kras and mutant Braf. In cancers with wild-type Braf, sorafenib and Raf 
inhibitors like PLX4720/PLX4032 transactivate Raf dimers and thus activating the 
Raf/MEK/ERK signaling pathway [22]. Other studies have been carried out to investigate 
mechanisms of resistance to selective Braf inhibitors in CRC and suggested that resistance to 
Braf inhibition is also mediated by EGFR-reactivation of the Raf/MEK/ERK signaling 
pathway [23]. Mao et al. also demonstrated that presence of activating mutations of PI3K or 
PTEN activates the PI3K/AKT signaling pathway in CRC cells, which also reduced the 
sensitivity towards Raf inhibitor treatment [24]. Therefore in order to have a potent anti-
tumor effect, a thorough determination of the genetic status [22,25,26] and a personalized 
combination therapy with other inhibitors of the Raf/MEK/ERK and PI3K/AKT signaling 
pathways are needed. This hindered the application of Raf inhibitors on clinical studies. As 
Raf265 was found to be effective in inhibiting the growth of wild-type Braf CRC cells, it is 
worthwhile to continue the clinical study of the effect of Raf265 on CRC patients with Braf 
mutation and Kras mutation. 
In mCRC patients, 5FU-based chemotherapy remains the most commonly prescribed anti-
cancer therapy. 5FU inhibits the growth of rapidly dividing cells mainly through the 
inhibition of DNA synthesis. However, it is non-selective and can affect normal fast-growing 
cells including cells in the hair follicles, bone marrow and the gastrointestinal tract. Intrinsic 
and acquired chemoresistance can occur which may increase the chance of enriching CSCs 
population. A recent study from our team suggests that chemotherapy with 5FU enrich a 
subpopulation of CD26+ cells with CSCs properties in mouse xenograft model [6]. In this 
study, enriched CD26+ subpopulation was found in 5FU resistant cells, which are sensitive 
towards Raf265 treatment. From tumor samples, a higher BRAF expression with an enhanced 
phosphorylation of MEK and ERK was also demonstrated in CD26+ cells when compared 
with that of the CD26− cells. 
We further demonstrated that Raf265 was effective in enhancing the anti-tumor effect of 5FU 
treatment but preventing metastasis by targeting on the CD26+ cells. These findings 
suggested the possible combination of Raf265 and 5FU in treating mCRC. Other clinical 
studies also suggested the efficacy of certain molecular targeted agents can be enhanced by 
combining them with chemotherapy. For example, when cetuximab, a monoclonal antibody 
directed against EGFR, is combination with irinotecan, response rates in irinotecan-refractory 
metastatic CRC patients has been improved with the mean survival time increased from 6.9 
months (monotherapy with cetuximab alone) to 8.6 months (combined therapy with 
cetuximab and irinotecan) [27]. When bevacizymab, a monoclonal antibody targeted against 
VEGF-A, was added to a fluorouracil-based combination chemotherapy, the overall survival 
rates in patients with metastatic colon cancer can be improved [28]. 
Conclusions 
Raf265 reduced cell proliferation and enhanced cellular apoptosis in CRC cells through the 
inhibition of the Raf/MEK/ERK signaling pathway. In vivo study also demonstrated the anti-
tumor effect of Raf265 on mouse xenograft tumor. Although 5FU treatment enriched a 
subpopulation of CD26+ cells, which enhanced the migratory and invasive ability of colon 
cancer, combination treatment with Raf265 reversed the 5FU effect by targeting on the 
CD26+ cells and in vivo study demonstrated a significant inhibition of liver and lung 
metastasis. Therefore, this pre-clinical data demonstrate the anti-tumor and anti-metastatic 
activity of Raf265 in CRC, providing the basis for exploiting its potential use and 
combination therapy with 5FU in the clinical treatment of CRC. 
Methods 
Drugs and reagents 
Raf265 was provided by Novartis Pharmaceuticals Corporation. All reagents were purchased 
from Sigma-Aldrich (St. Louis, MO, USA), unless specified below. 
Cell culture and treatment 
HT29 (CCL-225) and HCT116 (CCL-247) (obtained from ATCC, Manassas, VA in 2010) 
were maintained in DMEM (Life Technologies, Carlsbad, CA) containing 10% FBS (Life 
Technologies) and 1% Penicillin/Streptomycin (Life Technologies), at 37°C humidified 
incubator with 5% CO2 in the air and have not been authenticated by the authors. Shortly 
after purchase, both cell lines were stably transfected with luciferase expressing construct for 
the ease of detection in the in vivo study. 
Development of 5FU resistant cells (5FU-R) 
For the development of 5FU resistant cells (5FU-R), HT29 cells were treated with 1 µM 5FU 
and the concentration of 5FU was increased by 10% every two weeks until the maximum 
tolerated dose has been reached and 5FU resistance has been developed. Equal volume of 
DMSO was added in parallel to the control cells (CTL) to eliminate the vehicle effect during 
the process. 
Sample collection and isolation of CD26+ and CD26− CSCs 
5 fresh tumor specimens were obtained with informed consent from patients who underwent 
surgical resection of primary colorectal cancer at the Department of Surgery, Queen Mary 
Hospital, The University of Hong Kong. The study was approved by the Institutional Review 
Board (HKU/HA HKW). Once obtained, tumor specimens were enzymatically disaggregated 
as mentioned before [6]. Isolation of CD26+ and CD26− CSCs from disaggregated tumor 
samples, HT29 cells and HCT116 cells was performed by fluorescent-activated cell sorting 
(FACS) as mentioned before [6]. The sorted cells were treated with Raf265 in mTeSRTM1 
medium (STEMCELL Technologies, Vancouver, CA, Canada) for the annexin V analysis. 
Cell proliferation and soft agar colony formation assay 
The effect of Raf265 on cell proliferation was first examined by MTT assay as previously 
described [29]. Briefly, cells were plated in 96-well culture plates for 24 hours and media 
were replaced with culture medium with the indicated concentrations of Raf265. After 72 
hours, viability was assessed with the addition of MTT solution (1 mg/ml) (Life 
Technologies). The percentage of surviving cells was determined by dividing the average 
absorbance of Raf265-treated cells by the average absorbance of untreated cells. 
The proliferation rate of HT29 cells and HCT116 cells was also analyzed using soft agar 
assay. Cells were suspended in 0.7% microbiology grade agarose in culture medium with the 
indicated concentrations (0, 0.1 and 1 µM) of Raf265 and layered on top of a solidified 
bottom layer of 0.9% agarose with corresponding concentration of Raf265 in culture medium 
in six-well plates. After 3 weeks of incubation, the numbers of colony in 4 randomly selected 
fields with 40x magnification was counted. 
Sphere formation assay 
The effect of Raf265 on the self-renewal ability of CD26+ cells was examined by serial 
passage of cells in the sphere formation assay. CD26+ cells with single cell suspensions in 
mTeSRTM1 medium were incubated with indicated concentrations (0, 0.1 and 1 µM) of 
Raf265 and cultured on ultra low attachment plates (Corning Inc., Corning, NY). The 
numbers of sphere in each well were quantified after 14 days. Spheres were then 
disaggregated and reseeded with the indicated concentrations of Raf265 to evaluate self-
renewal by formation of secondary passage of spheres and the numbers of sphere were 
quantified again after 14 days of incubation. 
Annexin V analysis by flow cytometry 
The effect of Raf265 on cellular apoptosis was examined by Annexin V: PE & PI apoptosis 
detection kit (BD Biosciences, CA) according to the instructions of the company. Briefly, 1 x 
106 cells were grown in 6-well plates. After 24 h, cells were treated with the indicated 
concentrations (1, 5, 10 and 15 µM) of Raf265 for 48 h. Cells were harvested, washed with 
PBS, and stained with annexin V/PI mixture in binding buffer for 15 min at room temperature 
in dark. Apoptotic cells were determined by Cytomics FC 500 flow cytometer (Beckman 
Coulter, CA) and analyzed using FlowJo (version 8.7, Tree Star, Inc.). 
Caspase 3, 8 and 9 activities by flow cytometry 
The effect of Raf265 on caspase activity was examined by flow cytometry using 
CaspGLOWTM Red Active caspase 3, caspase 8 and caspase 9 staining kits (BioVision, CA) 
according to the manufacturer’s instructions. Briefly, 1 x 106 cells were grown in 6-well 
plates. After 24 h, cells were treated with the indicated concentrations (1 and 10 µM) of 
Raf265 for 48 h. Cells were harvested, washed with PBS, and incubated with specific caspase 
inhibitor conjugated to sulfo-rhodamine (Red-DEVD-FMK, Red-IETD-FMK, and Red-
LEHD-FMK for detection of caspase 3, caspase 8, and caspase 9, respectively) in 300 µl of 
culture medium at 37°C incubator with 5% CO2 for 1 h in dark. After washed with PBS 
twice, stained cells were analyzed by flow cytometry and analyzed using FlowJo. 
Western blotting analysis 
Cells were treated with the indicated compounds in DMEM containing 1% BSA for 4 h for 
the study of phosphorylation of MEK1/2, p44/42 MAPK (ERK1/2), and Akt. 10 µM U0126, 
an MEK 1/2 inhibitor, was added as a control. Cell were then lysed by ice-cold RIPA 
containing 150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40, 0.25% (w/v) sodium deoxycholate, 
1 mM PMSF, and protease inhibitor cocktail (Roche Diagnostics, Penzberg, Germany) in 50 
mM Tris–HCl buffer, pH 7.4. Equal amount of protein was loaded onto a 12.5% SDS-
polyacrylamide gel under reducing condition and transferred to PVDF membrane (Amersham 
Bioscience, Piscataway, NJ). Blots were probed with the following antibodies: MEK1/2, 
phospho-MEK1/2, ERK1/2, phospho-ERK1/2, Akt (pan), phospho-Akt, and Braf (Cell 
Signaling, Danvers, MA) and β-actin (Sigma-Aldrich) was used as loading control. After 
probing with horseradish peroxidase-conjugated secondary antibodies, membranes were 
developed with the Immobilon Western Chemiluminescent HRP substrate system (Millipore). 
Treatment with Raf265 and 5FU on CD26 distribution 
After treatment of 5FU sensitive (CTL) and resistant (5FU-R) cells with Raf265 and 5FU, 
cells were harvested and stained with CD26-FITC antibody (BD Pharmingen). The 
percentage of CD26+ cells was determined by Cytomics FC 500 flow cytometer (Beckman 
Coulter, CA) and analyzed using FlowJo (version 8.7, Tree Star, Inc.). 
Migration and invasion transwell assay 
After treatment with different combinations of drugs for 48 hours, HCT116 cells were plated 
in top chambers of 24-well transwell plates with 8 µm pores (Corning) and 24-well 
BioCoat™ Matrigel™ Invasion chamber (BD Biosciences) at 1x105 cells per well in DMEM 
with 1% FBS, for the study of migration and invasion, respectively. 10% FBS was used as 
chemoattractant. After 96 hours incubation, migrated or invaded cells were stained with 0.2% 
crystal violet. The numbers of migrated and invaded cells in four fields were counted under 
100x magnification and the average numbers of migrated and invaded cells were counted. 
In vivo study 
Animal study was approved by the Committee on the Use of Live Animals for Teaching and 
Research of the University of Hong Kong (CULTR no. 2407–11). Nude or NOD/SCID mice 
were maintained in laminar flow cabinets under pathogen-free conditions. For the xenograft 
model, HT29 or HCT116 cells were harvested from mid-log phase cultures and resuspended 
in a 50% Matrigel in culture medium. 200 µl cells were injected subcutaneously into the right 
flank of 6 nude mice of each group to induce xenograft tumor formation. 2 weeks after 
injection, 0.2 mg/kg Raf265 was administered i.p. twice weekly for 16 weeks. Caliper 
measurement of tumor dimensions were done every 4 weeks for the estimation of tumor 
weight by the formula π/6 x l x w2 where l is the length and w is the width of the tumor. Mice 
were sacrificed at week 16 and the xenograft tumor tissue were formalin-fixed and paraffin-
embedded. 
For the orthotropic model, a xenograft tumor raised from HT29 or HCT116 cells was 
dissected into 2 mm3. Cecum was exteriorized by laparotomy and the dissected tumor cube 
was inoculated into the cecal wall of NOD/SCID mice. 3 weeks after inoculation, Raf265 was 
administered p.o. twice a week whereas 5FU was administered i.p. once a week for 4 weeks. 
Mice were sacrificed at week 4. Ten minutes before imaging, an intraperitoneal injection of 
15 mg/kg body weight D-luciferin (Life Technologies) was administered to the anesthetized 
mice. Whole body images and organ images of bioluminescent signals were acquired by the 
in vivo imaging system Xenogen IVIS 100 (Xenogen, Alameda, CA). Regions of interest 
(ROI) were manually selected, and the results were quantified as average radiance of photons 
emitted per second and area (p/s/cm2) by using the Living Image 2.50.2 software (Xenogen). 
Immunohistochemistry (IHC) staining of CD31 
The paraffin-embedded tissues were sectioned, deparaffinized and rehydrated through a 
series of xylenes and ethanol. Antigen retrieval was performed by boiling in sodium citrate 
buffer (10 mmol/L sodium citrate, pH 6.0). Slides were then incubated with anti-CD31 
(Abcam) overnight at 4°C and signal was detected by the LSAB+ System-HRP kits (Dako) 
according to the manufacturer’s instruction. Sections were then counterstained with 
hematoxylin and dehydrated through a series of ethanol and xylenes. 
Statistical analysis 
Data are presented as means ± SD from three independent experiments for the in vitro study 
and from n = 6 for the in vivo study. Data were statistically analyzed with one-way ANOVA, 
and were considered statistically significant at p < 0.05. 
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